iPS Cells & Regenerative Medicine– category –
-
uBriGene Launches uVivo Lentiviral Vector Platform to Accelerate Next-Generation In Vivo CAR T Therapies
Morningstar (Provided by ACCESS Newswire) Unknown Overview uBriGene has introduced its uVivo lentiviral vector platform, designed to significantly accelerate the development of next-generation in vivo CAR T-cell therapies. This platform ... -
Auxilium Biotechnologies Achieves World-First Space Bioprinting of Functional Kidney and Liver Tissues on ISS
Business Wire USA Overview Auxilium Biotechnologies successfully bioprinted kidney and liver tissues aboard the International Space Station using its AMP-1 orbital bioprinter, marking the first time these complex tissue types have been p... -
Allogene’s ALLO-316 Allogeneic CAR T Achieves First Durable Remissions with 31% ORR in Phase 1 Metastatic Renal Cell Carcinoma Trial
BioSpace USA Overview Allogene Therapeutics announced compelling Phase 1 results for ALLO-316, a CD70-targeted allogeneic CAR T therapy, demonstrating a 31% confirmed objective response rate and the first durable remissions in metastatic... -
Novel Stem Cell Approach Aims for Functional Cure in Diabetes, Pioneering Immunosuppression-Free Islet Cell Transplantation
News-Medical International Overview A new stem cell approach is targeting a functional cure for diabetes, specifically focusing on the potential for islet cell transplantation without immunosuppression, as reported on July 11, 2026. This... -
Kite and BBG Advanced Therapies Launch Mobile Leukapheresis Center in Texas to Enhance CAR T-Cell Therapy Patient Access and Streamline Supply Chain
Cellgenetherapyreview.com USA Overview Kite and BBG Advanced Therapies announced on July 9, 2026, the launch of a mobile leukapheresis center in Texas. This innovative initiative aims to significantly improve access to the apheresis proc... -
Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases
Cellgenetherapyreview.com USA Overview On July 10, 2026, Wugen announced its rebranding to Allotera and the successful completion of a $35 million financing round. This rebranding and capital infusion represent a significant strategic st... -
Lyora Launches with Seed Funding to Propel Ophthalmic Gene Therapy Assets, Targeting IND Submission Within 18 Months
Cellgenetherapyreview.com USA Overview Lyora announced on July 14, 2026, the successful completion of its seed funding round and the official launch of operations, aimed at advancing its ophthalmic gene therapy assets. The company plans ... -
Ocugen Forges Strategic Alliance to Bring Broad-Spectrum OCU400 Gene Therapy to MENA Region
Cellgenetherapyreview.com USA, Middle East and North Africa Overview Ocugen, Inc. announced on July 15, 2026, an exclusive licensing agreement with Roots Pharma and Al-Dhow International to commercialize OCU400, its innovative modifier g... -
Human Organoid Technology: A Review of Latest Developments and Applications Driving Disease Mechanism Discovery and Personalized Medicine
PubMed (Organoid journal) International Overview This review article, published on July 10, 2026, outlines the latest developments and applications of human organoid technology, highlighting its unique capacity for in vitro research into... -
Organoid Research Showcased at ISSCR 2026: iPSC and Adult Stem Cell-Derived Systems Drive Breakthroughs in Organogenesis and Disease Modeling
International Society for Stem Cell Research (ISSCR) International Overview The ISSCR 2026 annual meeting highlighted the latest innovations and technical advancements in organoid technology, particularly emphasizing iPSC and adult stem ...
